Rockville, MD and Beijing, China (Press Release) – CASI Pharma­ceu­ticals, Inc. (Nasdaq: CASI), a U.S. bio­pharma­ceu­tical com­pany focused on devel­op­ing and com­mer­cializing inno­va­tive thera­peutics and pharma­ceu­tical prod­ucts, to­day an­nounced that it sub­mitted a Clinical Trial Appli­ca­tion (CTA) (IND) with the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for CID-103, its novel anti-CD38 mono­clonal anti­body for the treat­ment of mul­ti­ple myeloma and other hema­to­logical malig­nan­cies.

Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "Submitting this CTA is an im­por­tant step in the clin­i­cal de­vel­op­ment of this promising ther­apy in our …